Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
Public ClinicalTrials.gov record NCT00332956. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 (a), Dose-Blinded, Block-Randomized, Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210. Additional immunogenicity and safety/reactogenicity data will be collected through Day 540. Selection of dosage and schedule will be based on GMCs and seroconversion rates for anti-F1, anti-V and anti-rF1V antibody titers. Approximately 400 healthy adult volunteers will be enrolled (100 per group) in this study.
Study identification
- NCT ID
- NCT00332956
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Interventions
- rFIV vaccine Biological
- rF1V vaccine Biological
- rF1V vaccine 160 mcg given on Study Days 0, 56, 182 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2006
- Primary completion
- Jan 31, 2008
- Completion
- Sep 30, 2008
- Last update posted
- Dec 1, 2011
2006 – 2008
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alta Clinical Research, LLC | Tucson | Arizona | 85745 | — |
| Benchmark Research | San Francisco | California | 94102 | — |
| Palm Beach Research | West Palm Beach | Florida | 33409 | — |
| University of Kentucky - Dept. of Infectious Disease | Lexington | Kentucky | 40536 | — |
| Sundance Clinical Research | St Louis | Missouri | 63141 | — |
| Infectious Disease Specialists, PC | Missoula | Montana | 59802 | — |
| Meridian clinical Research, LLC | Omaha | Nebraska | 68134 | — |
| Clinical Research Center of Nevada | Las Vegas | Nevada | 89104 | — |
| Primary Physicians Research, Inc. | Pittsburgh | Pennsylvania | 15241 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00332956, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2011 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00332956 live on ClinicalTrials.gov.